2-(3-Ethyl-5-hydroxy-5-trifluoromethyl-4,5-dihydro-pyrazol-1-yl)-N-(2-methoxy-phenyl)-2-oxo-acetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(3-Ethyl-5-hydroxy-5-trifluoromethyl-4,5-dihydro-pyrazol-1-yl)-N-(2-methoxy-phenyl)-2-oxo-acetamide
• 英文别名: 2-[3-ethyl-5-hydroxy-5-(trifluoromethyl)-4H-pyrazol-1-yl]-N-(2-methoxyphenyl)-2-oxoacetamide
• 化学式: C₁₅H₁₆F₃N₃O₄
• 分子量: 359.3
• InChiKey: NOPVUINLBZUXCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  91.2
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• METHODS OF ENHANCING COGNITIVE FUNCTION USING NON-PEPTIDIC COMPOUNDS
  申请人：Acumen Pharmaceuticals, Inc.

  公开号：EP2173340B1

  公开（公告）日：2013-07-10
• METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS
  申请人：KRAFFT Grant A.

  公开号：US20090018084A1

  公开（公告）日：2009-01-15

  Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from Aβ 1-42 monomers.
• METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42
  申请人：ACUMEN PHARMACEUTICALS, INC.

  公开号：US20150320860A1

  公开（公告）日：2015-11-12

  This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils, wherein the antibody is in combination with a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
• US8962677B2
  申请人：——

  公开号：US8962677B2

  公开（公告）日：2015-02-24
• [EN] METHODS OF ENHANCING COGNITIVE FUNCTION USING NON-PEPTIDIC COMPOUNDS<br/>[FR] PROCÉDÉS D'AMÉLIORATION DE LA FONCTION COGNITIVE EN UTILISANT DES COMPOSÉS NON PEPTIDIQUES
  申请人：ACUMEN PHARMACEUTICALS INC

  公开号：WO2009008891A1

  公开（公告）日：2009-01-15

  Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from Aß1-42 monomers.